SOURCE-LINKED STUDY SUMMARY
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
Abstract summarizedQuality not appraised
- What was studied
- A propensity-matched observational cohort compared on-treatment weight loss and gastrointestinal adverse events among adults receiving tirzepatide or semaglutide in routine care.
- Who / model studied
- Adults with overweight or obesity were identified from linked US health-record and dispensing data; participants had no prior GLP-1 receptor agonist use.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Tirzepatide use was associated with greater weight loss than semaglutide, while gastrointestinal adverse-event rates were similar.
- Limitations & context
- This was an observational on-treatment study with substantial treatment discontinuation, so it cannot establish comparative causal effects.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jamainternmed.2024.2525